JHVEPhoto/iStock Editorial via Getty Images
- Novo Nordisk (NVO) has brokered a collaboration agreement with privately held Deep Apple Therapeutics to develop oral drugs aimed at a novel non-incretin GPCR target for obesity and other cardiometabolic diseases.
- Terms call for Deep Apple to discover compounds using